NA
ESPR

NewEdge Advisors’s Esperion Therapeutics ESPR Stock Holding History

NewEdge Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-600
Closed -$1.59K – 4267
2025
Q3 		$1.59K Hold
600
– – ﹤0.01% 3823
2025
Q2 		$591 Hold
600
– – ﹤0.01% 3781
2025
Q1 		$864 Hold
600
– – ﹤0.01% 3650
2024
Q4 		$1.32K Hold
600
– – ﹤0.01% 3522
2024
Q3 		$990 Sell
600
-100
-14% -$202 ﹤0.01% 3510
2024
Q2 		$1.55K Buy
700
+100
+17% +$235 ﹤0.01% 3381
2024
Q1 		$1.61K Hold
600
– – ﹤0.01% 3419
2023
Q4 		$1.79K Hold
600
– – ﹤0.01% 3357
2023
Q3 		$588 Hold
600
– – ﹤0.01% 3232
2023
Q2 		$834 Sell
600
-8,222
-93% -$11.5K ﹤0.01% 3274
2023
Q1 		$14K Buy
8,822
+8,222
+1,370% +$42.4K ﹤0.01% 2460
2022
Q4 		$4 Buy
+600
New +$4.29K ﹤0.01% 3837

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

NewEdge Advisors's ESPR Position: Q4 2025 in Review

NewEdge Advisors sold out of Esperion Therapeutics (ESPR) in Q4 2025, closing a stake of 600 shares — an estimated $1.59K sold.

NewEdge Advisors first reported a position in ESPR in Q4 2022 and held it in 12 quarters. The position peaked at $14K in Q1 2023. 200 funds tracked by Wall St. Rank hold ESPR as of Q4 2025.

  • NewEdge Advisors reported no remaining Esperion Therapeutics position as of Q4 2025 after selling out during the quarter.
  • NewEdge Advisors sold 600 Esperion Therapeutics shares in Q4 2025, an estimated $1.59K.
  • NewEdge Advisors first reported a position in Esperion Therapeutics in Q4 2022 and held it in 12 quarters.
  • NewEdge Advisors's Esperion Therapeutics position peaked at $14K in Q1 2023.
  • 200 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2025.

Based on NewEdge Advisors's 13F filing for Q4 2025, filed 18 Feb 2026.